Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO), has been at the forefront of biologic development and manufacturing for over 40 years. Our value chain encompasses the whole process: from gene to vial and from concept to market. As a full-service provider, Rentschler Biopharma offers its clients one primary contact, with only one contract signed for all phases of a development cycle. As a provider of high-end solutions for our partners, we help clients transition a project…
Author Archives: Federico Pollano
Early Stage Development of Advanced Formulations in the Drug Development Process Provides Competitive Advantages: Survey Predicts That Drug Product Formulation Recognition and Budgets Will Increase Significantly
New antibody formats and aggregate-prone, subcutaneously administered protein therapeutics present biopharmaceutical companies with major challenges regarding protein stability and aggregation. At the same time, protein stability often is not given enough attention in early stages of development. Protein aggregation reduces drug activity so that increasing doses are needed to achieve the same desired effect. Even worse, protein aggregates can induce immunogenecity that endangers patients and compromises product approval. A market study presented for the first time at the Bio-Europe 2018…
A World-Class Biopharmaceutical CDMO
Rentschler Biopharma SE — located in Laupheim, Germany — is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company’s clients include innovative biotech companies and major pharmaceutical companies around the world. Rentschler Biopharma has long-standing experience and proven excellence as a solution partner of choice. A top-notch quality management system, well-established operational excellence, and advanced technologies ensure product quality at each development and manufacturing step. Rentschler Biopharma is a family-owned company with over 850…